{"transactions":[{"id":692991,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-08T01:47:17.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":782854,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering (\"IPO\"), for no consideration. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering (\"IPO\"), for no consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering (\"IPO\"), for no consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering (\"IPO\"), for no consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Redmile Biopharma Investments III, L.P. (\"RBI III\"), which is managed by Redmile Group, LLC (\"Redmile\"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":782854},"source":{"system":"sec-edgar","filing":"0001104659-26-092867","document":"tm2622627-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926092867/tm2622627-1_4seq1.xml","form_type":"4"}},{"id":692990,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-08T01:47:17.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":17,"value":6800000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities were purchased in the IPO by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), and include the number of securities purchased by RBI III in the IPO reported in the line above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1182854,"source":{"system":"sec-edgar","filing":"0001104659-26-092867","document":"tm2622627-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926092867/tm2622627-1_4seq1.xml","form_type":"4"}},{"id":692989,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-08T01:47:17.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":17,"value":3400000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held directly by Redmile Biopharma Investments III, L.P. (\"RBI III\"), which is managed by Redmile Group, LLC (\"Redmile\"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":982854,"source":{"system":"sec-edgar","filing":"0001104659-26-092867","document":"tm2622627-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926092867/tm2622627-1_4seq1.xml","form_type":"4"}},{"id":692988,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-08T01:47:17.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":782854,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering (\"IPO\"), for no consideration. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Redmile Biopharma Investments III, L.P. (\"RBI III\"), which is managed by Redmile Group, LLC (\"Redmile\"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":782854,"source":{"system":"sec-edgar","filing":"0001104659-26-092867","document":"tm2622627-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465926092867/tm2622627-1_4seq1.xml","form_type":"4"}},{"id":2524559,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-11-05T01:00:33.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":954420,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954420},"source":{"system":"sec-edgar","filing":"0001104659-21-134623","document":"tm2131859-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921134623/tm2131859-1_4seq1.xml","form_type":"4"}},{"id":2524558,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-05T01:00:33.000Z","date":"2021-11-02","kind":"purchase","acquired":true,"shares":1000000,"price":20,"value":20000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects number of shares owned as of November 2, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1954420,"source":{"system":"sec-edgar","filing":"0001104659-21-134623","document":"tm2131859-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921134623/tm2131859-1_4seq1.xml","form_type":"4"}},{"id":2524557,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25416,"kind":"organization","name":"Redmile Biopharma Investments III, L.P.","position":3,"cik":"0001838746","reported_name":"Redmile Biopharma Investments III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-05T01:00:33.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":954420,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Managing Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":954420,"source":{"system":"sec-edgar","filing":"0001104659-21-134623","document":"tm2131859-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921134623/tm2131859-1_4seq1.xml","form_type":"4"}}]}